[HTML][HTML] Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei, H Wang… - Journal of Translational …, 2023 - Springer
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
[HTML][HTML] Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei, H Wang… - Journal of …, 2023 - ncbi.nlm.nih.gov
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
[HTML][HTML] Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin… - Journal of …, 2023 - … -medicine.biomedcentral.com
The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning method for
the treatment of liver cirrhosis. However, the secretory phenotype and regulatory ability of …
the treatment of liver cirrhosis. However, the secretory phenotype and regulatory ability of …
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils.
Y Xie, J Yao, M Yan, Y Lin, J Wei… - Journal of …, 2023 - search.ebscohost.com
Background: The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei… - Journal of …, 2023 - search.proquest.com
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei, H Wang… - Journal of …, 2023 - europepmc.org
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
[PDF][PDF] Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
Y Xie, J Yao, M Yan, Y Lin, J Wei, H Wang… - 2023 - … -medicine.biomedcentral.com
Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils.
Y Xie, J Yao, M Yan, Y Lin, J Wei, H Wang… - Journal of …, 2023 - europepmc.org
The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning method for
the treatment of liver cirrhosis. However, the secretory phenotype and regulatory ability of …
the treatment of liver cirrhosis. However, the secretory phenotype and regulatory ability of …